New issues for copper-64

from precursor to innovative PET tracers in clinical oncology.

Laura Evangelista, Mansi Luigi, Giuseppe Lucio Cascini

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The role of copper in the metabolism of human cancer cells has been largely investigated in the last 20 years and a strong relationship between copper levels and cancer progression has been demonstrated. Moreover copper is involved in tumor angiogenesis as well as in non-neoplastic conditions like neurodegenerative diseases. The main mechanism of action is related to a cellular transporter (CTR1) that plays a pivotal role in preserving the intra-cellular homeostasis, allowing at the same time the anti- tumor activity of platinum based therapies. Copper-64, emitting positrons and β- radiations, is suitable for the labeling of a large number of molecules that could be used for radionuclide imaging, being also usable in radionuclide therapy. Nevertheless few data are at present available on radiotracers labeled with radiocopper and in particular on the use of (64)Cu-Cl2 in cancer patients. In this paper we analyze the potential applications for Copper-64 as PET agent in the clinical oncological scenario.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalCurrent Radiopharmaceuticals
Volume6
Issue number3
Publication statusPublished - Sep 2013

Fingerprint

Medical Oncology
Copper
Neoplasms
Platinum
Radioisotopes
Radionuclide Imaging
Neurodegenerative Diseases
Homeostasis
Electrons
Radiation
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

New issues for copper-64 : from precursor to innovative PET tracers in clinical oncology. / Evangelista, Laura; Luigi, Mansi; Cascini, Giuseppe Lucio.

In: Current Radiopharmaceuticals, Vol. 6, No. 3, 09.2013, p. 117-123.

Research output: Contribution to journalArticle

@article{936f0d92ef8b4b0eacbe455b66cb840e,
title = "New issues for copper-64: from precursor to innovative PET tracers in clinical oncology.",
abstract = "The role of copper in the metabolism of human cancer cells has been largely investigated in the last 20 years and a strong relationship between copper levels and cancer progression has been demonstrated. Moreover copper is involved in tumor angiogenesis as well as in non-neoplastic conditions like neurodegenerative diseases. The main mechanism of action is related to a cellular transporter (CTR1) that plays a pivotal role in preserving the intra-cellular homeostasis, allowing at the same time the anti- tumor activity of platinum based therapies. Copper-64, emitting positrons and β- radiations, is suitable for the labeling of a large number of molecules that could be used for radionuclide imaging, being also usable in radionuclide therapy. Nevertheless few data are at present available on radiotracers labeled with radiocopper and in particular on the use of (64)Cu-Cl2 in cancer patients. In this paper we analyze the potential applications for Copper-64 as PET agent in the clinical oncological scenario.",
author = "Laura Evangelista and Mansi Luigi and Cascini, {Giuseppe Lucio}",
year = "2013",
month = "9",
language = "English",
volume = "6",
pages = "117--123",
journal = "Current Radiopharmaceuticals",
issn = "1874-4710",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - New issues for copper-64

T2 - from precursor to innovative PET tracers in clinical oncology.

AU - Evangelista, Laura

AU - Luigi, Mansi

AU - Cascini, Giuseppe Lucio

PY - 2013/9

Y1 - 2013/9

N2 - The role of copper in the metabolism of human cancer cells has been largely investigated in the last 20 years and a strong relationship between copper levels and cancer progression has been demonstrated. Moreover copper is involved in tumor angiogenesis as well as in non-neoplastic conditions like neurodegenerative diseases. The main mechanism of action is related to a cellular transporter (CTR1) that plays a pivotal role in preserving the intra-cellular homeostasis, allowing at the same time the anti- tumor activity of platinum based therapies. Copper-64, emitting positrons and β- radiations, is suitable for the labeling of a large number of molecules that could be used for radionuclide imaging, being also usable in radionuclide therapy. Nevertheless few data are at present available on radiotracers labeled with radiocopper and in particular on the use of (64)Cu-Cl2 in cancer patients. In this paper we analyze the potential applications for Copper-64 as PET agent in the clinical oncological scenario.

AB - The role of copper in the metabolism of human cancer cells has been largely investigated in the last 20 years and a strong relationship between copper levels and cancer progression has been demonstrated. Moreover copper is involved in tumor angiogenesis as well as in non-neoplastic conditions like neurodegenerative diseases. The main mechanism of action is related to a cellular transporter (CTR1) that plays a pivotal role in preserving the intra-cellular homeostasis, allowing at the same time the anti- tumor activity of platinum based therapies. Copper-64, emitting positrons and β- radiations, is suitable for the labeling of a large number of molecules that could be used for radionuclide imaging, being also usable in radionuclide therapy. Nevertheless few data are at present available on radiotracers labeled with radiocopper and in particular on the use of (64)Cu-Cl2 in cancer patients. In this paper we analyze the potential applications for Copper-64 as PET agent in the clinical oncological scenario.

UR - http://www.scopus.com/inward/record.url?scp=84901564184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901564184&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 117

EP - 123

JO - Current Radiopharmaceuticals

JF - Current Radiopharmaceuticals

SN - 1874-4710

IS - 3

ER -